Facebook
Twitter
LinkedIn
WhatsApp

Stage 4 Cancer

Stage 4, Stage IV metastatic cancer

“Metastases cancer” or stage 4 cancer, is the medical term for describing a condition where a tumor originating in a certain organ, “primary tumor”, is identified in another organ or in a distant location from the original organ, e.g., metastases of breast cancer can be found in the lungs, brain, bones and liver.

It is important to note, metastases are the same type of the original primary tumor, even if its location is in distant organs and so are the treatments regarded as such, for example, a treatment for a metastatic lung cancer that has spread to the liver, is determined by the treatment for metastatic lung cancer and not by the treatment for liver cancer.

Metastases formation

Cancer cells of the primary tumor can be released into the bloodstream and lymphatic system and circulate to distant organs or adjacent organs and tissues to the primary tumor and “settle” in them and grow.

There are different types of cancer which is known where metastases can be formed, for example,

  • Breast cancer can spread to the bones, brain, liver and lungs
  • Lung cancer can spread to the brain, bones, liver and kidney
  • Prostate cancer can spread to the bones
  • Colon cancer, rectal cancer, colorectal cancer can spread to the liver and lungs
Breast cancer can spread to the bones, brain, liver and lungs
Breast cancer can spread to the bones, brain, liver and lungs

Stage IV metastatic cancer and recovery

In the vast majority of the metastatic cases, the treatments do not cure. Treatment goals are slowing tumor growth rate, prolonging life and reducing the symptoms of the disease, improving the quality of life of the patient.

The efficacy of the treatments is affected by many factors, among them are the type of cancer, number of metastases (also called “lesions”) and their location, how much cancer the patient has in his or her body, growth rate of the tumor lesions, medical history of the patient, background diseases, microenvironment between the tumor cells themselves, resistance the tumor has developed to previous treatments and other.

Advanced treatments and clinical trials for stage 4

The National Cancer Institute (NCI) highlights the fact that for a certain group of metastatic cancer patients, the best treatment option is to join one of the many clinical trials existing worldwide aiming to increase their chances of therapeutic success.

This is also recommended by the USA national comprehensive cancer network, NCCN,  (USA national comprehensive cancer network)

“Patients with cancer should be encouraged to participate in clinical trials during all aspects of their diagnosis and treatment”

Currently, every patient will be offered the standard protocols described above. Sometimes the oncologist may suggest integrating these therapies with trials carried out in the Institute.

Advances in cancer therapies may be found in clinical trials prescribing cutting edge, interesting drugs, some of which have already been recognized by the FDA (US Food & Drug Administration) as “breakthrough treatments” and require further information input before being finally and fully approved.

An entire world of clinical trials and compassionate drugs and treatments are open and available worldwide. It is important to know which cutting edge treatments exist which patients can gain far more from them than the standard care offered.

For most patients with stage 4 metastatic cancer, current treatments are insufficiently effective. This gives rise to the need for innovative strategies with greater efficacy in fighting the disease.

Read our publications on innovative treatments for stage 4 metastatic cancer:

To check if our service suits your case
We need to talk

Improve therapeutic outcomes, prolong life and quality of life, is our main business.
We support access to and expand cancer treatments beyond the standard of care, with the most advanced and innovative treatment options in the world, personally matching the individual cancer patient’s medical condition and with the support of top tier oncologists.

Article categories

קטגוריות המאמרים

Popular topics

Facebook
Twitter
LinkedIn
WhatsApp

Cervical Cancer – Positive Results with VB10.16

Overview

Cervical cancer is a malignant tumor that grows in different parts of the cervix.

The vast majority of cervical cancers are linked to an infection by the human papillomavirus (HPV), which is a very common virus that gets transmitted through sexual contact.

Unfortunately, when cervical cancer advances (e.g., metastasis), its management becomes very challenging.

In this article, we will cover the preliminary results of a phase II clinical trial regarding VB10.16 with Tecentriq in the management of advanced cervical cancer. First, let us start by defining the two drugs.

What is VB10.16?

VB10.16 is a DNA vaccine that has three parts.

Each part encodes for a specific protein, including:

  • E6/E7 fusion protein of human papillomavirus (HPV), which is the leading cause of cervical cancer
  • Dimerization entity
  • A protein that binds to antigen-presenting cells (APCs)

The purpose of this vaccine is to stimulate innate antineoplastic immunological responses. The drug gets administered via an intramuscular injection.

The first protein stimulates the immune system to attack cancerous cells that contain HPV. However, antigen-presenting cells might interfere early on in the process, preventing this action from occurring. For this reason, scientists added the third protein that blocks APCs temporarily until E6/E7 get internalized within the cells.

What is Tecentriq ?

Tecentriq, also called Atezolizumab, is an anti-PD-L1 monoclonal antibody that aids in the following conditions:

  • Locally advanced or metastatic urothelial carcinoma
  • Metastatic non-squamous, non-small cell lung cancer (Nsq NSCLC)
  • PD_L1 positive unresectable locally advanced or metastatic triple-negative breast cancer
  • Extensive-stage small cell lung cancer.
  • BRAF V600 mutation-positive unresectable or metastatic melanoma

Today, however, we will discuss its role in treating advanced cervical cancer.

The interim results of a phase II clinical trial

This clinical trial combined VB10.16 with Tecentriq  to treat patients with advanced cases of cervical cancer. One of the inclusion criteria was the positivity of HPV16 in all patients.

The Response Rate (The percentage of patients in whom the cancer has decreased by at least 30% in volume or disappeared after treatment) for this treatment was around 21%, with two complete remissions and 6 partial responses. As for the control rate (The percentage of patients whose disease had stopped growing or decreased in size of tumor by at least 30%) was around 64%.

The Response Rate was 26%, and the Disease Control Rate was 77% in PD-L1-positive patients.

Those with a negative PD-L1 demonstrated a Response Rate of 17% and a Disease Control Rate of 58%.

These preliminary results show that a combination of VB10.16 with Tecentriq can give patients with advanced cervical cancer hope and extend survival.

The complete data of this trial will be available in 2023.

Takeaway message

The positive results of this clinical trial give hope to patients with advanced cervical cancer – a condition that is often thought to be rapidly fatal.

We hope that more trials of this kind get conducted to reach the best possible outcome for patients with advanced cases of cancer.

Talk to us so see if we can help you to actually get the most advanced treatments

TRIAL•IN Pharma

Because we, do not give up on life!

Contact us 24/7 –

Call center +44.2082.426.039

 Read more about Cervical cancer>>

Cervical Cancer - Positive Results with VB10.16
Cervical Cancer – Positive Results with VB10.16

No Cost service compatibility check
Please fill in the details and we will back to you as soon as possible

Improving therapeutic success, extending life and quality of life are our main business. We extend to metastatic cancer patients and patients with brain tumors, the most advanced treatment options in the world and the best experts in Israel and abroad.

Article categories

קטגוריות המאמרים

Popular topics